Carroll Investors’s ARK Genomic Revolution ETF ARKG Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q2
Sell
-178
Closed -$5K 39
2022
Q1
$5K Hold
178
﹤0.01% 139
2021
Q4
$8K Buy
+178
New +$12.3K ﹤0.01% 150

Other funds holding ARKG

Carroll Investors's ARKG Position: Q2 2022 in Review

Carroll Investors sold out of ARK Genomic Revolution ETF (ARKG) in Q2 2022, closing a stake of 178 shares — an estimated $5K sold.

Carroll Investors first reported a position in ARKG in Q4 2021 and held it in 2 quarters. The position peaked at $8K in Q4 2021. 333 funds tracked by Wall St. Rank hold ARKG as of Q2 2022.

  • Carroll Investors reported no remaining ARK Genomic Revolution ETF position as of Q2 2022 after selling out during the quarter.
  • Carroll Investors sold 178 ARK Genomic Revolution ETF shares in Q2 2022, an estimated $5K.
  • Carroll Investors first reported a position in ARK Genomic Revolution ETF in Q4 2021 and held it in 2 quarters.
  • Carroll Investors's ARK Genomic Revolution ETF position peaked at $8K in Q4 2021.
  • 333 funds tracked by Wall St. Rank held ARK Genomic Revolution ETF as of Q2 2022.

Based on Carroll Investors's 13F filing for Q2 2022, filed 26 Jul 2022.